cizutamig

Cizutamig is a **bispecific antibody** (T-cell engager, TCE) that targets **B-cell maturation antigen (BCMA, also known as TNFRSF17)** on B cells and **CD3** on T cells. By binding BCMA and CD3, cizutamig redirects T cells to eliminate BCMA-expressing B cells, mediating cytotoxicity against pathogenic B cells implicated in both hematologic malignancies and autoimmune diseases. Cizutamig was initially developed for **relapsed or refractory multiple myeloma (RRMM)**, where it has shown promising efficacy with a differentiated safety profile characterized by a low rate of cytokine release syndrome (CRS) and no observed ICANS. More recently, it is under clinical investigation for the treatment of various autoimmune disorders, including refractory seropositive rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myasthenia gravis, IgA nephropathy, and pemphigus. The drug shows potential for **deep and selective B-cell depletion** and early clinical data in autoimmune diseases support further investigation. Both intravenous and subcutaneous formulations are in clinical development[1][2][3][7][9].

Other names

CND106CND-106CND 106